Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase IV study of FSME-IMMUN 0.5 mL booster in adults (follow-up to Study 223)
2007-000440-27Phase 4Completed
- Sponsor
- Baxter International Inc.
- Start
- Jul 2007
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of FSME-IMMUN in tick-borne encephalitis (TBE), sponsored by Baxter International Inc. Primary endpoints: Seropositivity rate after first and second booster vaccination and Safety after second booster FSME-IMMUN 0.5 mL. Started Jul 2007; status: completed.
02
Drugs
FSME-IMMUN
03
Conditions
tick-borne encephalitis (TBE)
Beyond the preview
Go deeper on 2007-000440-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000440-27.